Inclusion Criteria:  IgA nephropathy confirmed by pathological biopsy within 8 years prior to randomization; Male or female aged ≥ 18 years old and ≤ 70 years old; Average 24-hour urine total protein ≥ 1 g/24 h Estimated GFR (using the CKD-EPI formula) > 30 mL/min per 1.73 m^2; Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.  Exclusion Criteria:  Patients with clinically significant abnormal laboratory tests at screening; Evidence of rapid eGFR decrease > 15 ml/min during screening; Renal or other organ transplantation prior to, or expected during, the study; Patients with secondary IgA nephropathy; Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with IgA deposition, or other pathological or clinical types of renal diseases that may confound the study data interpretation; Patients with history of any severe unstable cardiovascular and cerebrovascular events within 12 weeks prior to screening; Immunocompromised individuals.